‘Yttrium-90 continues to demonstrate excellent properties of a desired medical isotope for cancer treatment, said AMIC Chief Research Officer, Dr.8 million Abaxis, Inc. , a medical products company manufacturing point-of-care blood evaluation systems, today reported economic results for the 3rd fiscal one fourth ended December 31, 2012. Record quarterly highlights include: Revenues of $49.8 million, up 32 percent over last year's comparable quarter. THE UNITED STATES revenues of $41.8 million, up 31 percent over last year's comparable quarter. Medical marketplace revenues of $9.0 million, up 10 percent over last year's comparable quarter.The program, however, truly showcases our ability to provide significant, additive affected individual enrollments to accelerate trial timelines. That is noteworthy in diabetes especially, a therapeutic area with nuanced protocols and fierce competition for clinical trial participants increasingly. Smith stated that Acurian produced over 20,000 pre-qualified referrals through immediate mail to regional subsets of its data source of over eight million diabetes patients, along with advertising within traditional online and social networks deployed internationally. Acurian’s patient database houses over half of the diagnosed type 2 diabetics in the United States.